BAX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

20.10.25 18:00 Uhr

Werte in diesem Artikel

NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Baxter International, Inc. ("Baxter" or "the Company") (NYSE: BAX) and certain of its officers.

Bronstein, Gewirtz & Grossman, LLC (PRNewsfoto/Bronstein, Gewirtz & Grossman, LLC)

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Baxter securities between February 23, 2023 and July 30, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/BAX.

Case Details

The Complaint alleges that throughout the Class Period, Defendants misled investors by failing to disclose that: (1) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (2) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (3) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (4) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (5) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/BAX. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Baxter you have until December 15, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bax-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-baxter-international-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302587851.html

SOURCE Bronstein, Gewirtz & Grossman, LLC

In eigener Sache

Übrigens: Baxter International und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Baxter International

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Baxter International

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Baxter International Inc.

Wer­bung

Analysen zu Baxter International Inc.

DatumRatingAnalyst
16.10.2018Baxter International UnderweightBarclays Capital
28.07.2017Baxter International NeutralUBS AG
27.07.2017Baxter International OverweightBarclays Capital
14.07.2017Baxter International OutperformBMO Capital Markets
30.06.2017Baxter International OverweightCantor Fitzgerald
DatumRatingAnalyst
27.07.2017Baxter International OverweightBarclays Capital
14.07.2017Baxter International OutperformBMO Capital Markets
30.06.2017Baxter International OverweightCantor Fitzgerald
11.08.2015Baxter International OverweightBarclays Capital
10.07.2015Baxter International Market PerformBMO Capital Markets
DatumRatingAnalyst
28.07.2017Baxter International NeutralUBS AG
27.04.2017Baxter International Sector PerformRBC Capital Markets
26.10.2016Baxter International Sector PerformRBC Capital Markets
27.04.2016Baxter International Sector PerformRBC Capital Markets
13.07.2015Baxter International Sector PerformRBC Capital Markets
DatumRatingAnalyst
16.10.2018Baxter International UnderweightBarclays Capital
05.10.2011Baxter International sellCitigroup Corp.
06.10.2005Update Baxter International Inc.: ReduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Baxter International Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen